Complement Activation Is a Prominent Feature ofMOGAD
| Autor: | Luisa Klotz, Sudarshini Ramanathan, Catharina C. Gross, Christian W. Keller, Eva-Maria Wendel, Markus Reindl, Jan D. Lünemann, Russell C. Dale, Joseph A Lopez, Fabienne Brilot, Kevin Rostasy, Heinz Wiendl |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Myelin oligodendrocyte glycoprotein Pathogenesis Young Adult 03 medical and health sciences 0302 clinical medicine medicine Humans In patient Spectrum disorder Demyelinating Disorder Complement Activation Aged Autoantibodies 030304 developmental biology Aged 80 and over 0303 health sciences Neuromyelitis optica biology business.industry Multiple sclerosis Middle Aged medicine.disease 3. Good health Complement system Neurology Immunology biology.protein Female Myelin-Oligodendrocyte Glycoprotein Neurology (clinical) business 030217 neurology & neurosurgery Demyelinating Diseases |
| Zdroj: | Annals of Neurology. 90:976-982 |
| ISSN: | 1531-8249 0364-5134 |
| Popis: | Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated diseases (MOGAD) account for a substantial proportion of pediatric and adult patients who present with acquired demyelinating disorders. Its pathogenesis and optimal therapy are incompletely understood. We profiled systemic complement activation in adult and pediatric patients with MOGAD compared to patients with relapse-onset multiple sclerosis, patients with neuromyelitis optica spectrum disorder, pediatric control and adult healthy donors. Proteins indicative of systemic classical and alternative complement activation were substantially increased in patients with MOGAD compared to control groups. Elevated levels were detected in both adult and pediatric cases and in across all clinical syndromes. Complement inhibition should be explored for its therapeutic merit in patients with MOGAD. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text